490 related articles for article (PubMed ID: 24160757)
21. The properties of UDP-glucuronyltransferase for cannabinoids in rat liver microsomes.
Watanabe K; Kita M; Yamamoto I; Oguri K; Yoshimura H
J Pharmacobiodyn; 1983 Aug; 6(8):581-7. PubMed ID: 6315914
[TBL] [Abstract][Full Text] [Related]
22. Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro.
Chen D; Lin XX; Zhao Q; Xiao J; Peng SF; Xiao MF; Ouyang DS; Tan ZR; Wang YC; Peng JB; Zhang W; Chen Y
Xenobiotica; 2017 Sep; 47(9):778-784. PubMed ID: 27571049
[TBL] [Abstract][Full Text] [Related]
23. Interactions of cannabinoids with bovine serum albumin.
Haque SJ; Poddar MK
Biosci Rep; 1984 Mar; 4(3):239-43. PubMed ID: 6326885
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
25. Hepatic Enzymes Relevant to the Disposition of (-)-∆
Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2019 Mar; 47(3):249-256. PubMed ID: 30567877
[TBL] [Abstract][Full Text] [Related]
26. Hepatic biotransformation of non-psychotropic phytocannabinoids and activity screening on cytochromes P450 and UDP-glucuronosyltransferases.
Havlasek J; Vrba J; Zatloukalova M; Papouskova B; Modriansky M; Storch J; Vacek J
Toxicol Appl Pharmacol; 2023 Oct; 476():116654. PubMed ID: 37574147
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein.
Court MH; Mealey KL; Burke NS; Jimenez TP; Zhu Z; Wakshlag JJ
J Vet Pharmacol Ther; 2024 Jan; 47(1):1-13. PubMed ID: 37469115
[TBL] [Abstract][Full Text] [Related]
28. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol.
Stinchcomb AL; Valiveti S; Hammell DC; Ramsey DR
J Pharm Pharmacol; 2004 Mar; 56(3):291-7. PubMed ID: 15025853
[TBL] [Abstract][Full Text] [Related]
29. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Niesink RJ; Rigter S; Koeter MW; Brunt TM
Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
[TBL] [Abstract][Full Text] [Related]
30. Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN.
Järbe TU; Henriksson BG; Ohlin GC
Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):68-72. PubMed ID: 921403
[TBL] [Abstract][Full Text] [Related]
31. Computational Prediction of Inhibitors and Inducers of the Major Isoforms of Cytochrome P450.
Rudik A; Dmitriev A; Lagunin A; Filimonov D; Poroikov V
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144612
[TBL] [Abstract][Full Text] [Related]
32. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
33. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.
Qiu JX; Zhou ZW; He ZX; Zhang X; Zhou SF; Zhu S
Drug Des Devel Ther; 2015; 9():841-66. PubMed ID: 25733806
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes.
Kong TY; Kim JH; Kwon SS; Cheong JC; Kim HS; In MK; Lee HS
Arch Pharm Res; 2017 Jun; 40(6):727-735. PubMed ID: 28484907
[TBL] [Abstract][Full Text] [Related]
35. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.
McGinnity DF; Parker AJ; Soars M; Riley RJ
Drug Metab Dispos; 2000 Nov; 28(11):1327-34. PubMed ID: 11038161
[TBL] [Abstract][Full Text] [Related]
36. The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application.
Wójcikowski J; Basińska A; Daniel WA
Biochem Pharmacol; 2014 Jul; 90(2):188-95. PubMed ID: 24841887
[TBL] [Abstract][Full Text] [Related]
37. Identification of glucuronides as in vivo liver conjugates of seven cannabinoids and some of their hydroxy and acid metabolites.
Harvey DJ; Martin BR; Paton WD
Res Commun Chem Pathol Pharmacol; 1977 Feb; 16(2):265-79. PubMed ID: 847285
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids and Cytochrome P450 Interactions.
Zendulka O; Dovrtělová G; Nosková K; Turjap M; Šulcová A; Hanuš L; Juřica J
Curr Drug Metab; 2016; 17(3):206-26. PubMed ID: 26651971
[TBL] [Abstract][Full Text] [Related]
39. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.
Arellano AL; Papaseit E; Romaguera A; Torrens M; Farré M
CNS Neurol Disord Drug Targets; 2017; 16(5):554-566. PubMed ID: 28412920
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H
Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
